University of Oklahoma researchers over a six-month period studied the effects of London-based Parasym‘s noninvasive neurostimulation device on roughly 50 paroxysmal AFib patients — half receiving vagus nerve stimulation through the external ear’s tragus and the other half receiving sham treatment on the ear lobe.
After six months, the Parasym device reduced atrial fibrillation burden among patients actively using it by 85% compared to those receiving sham treatment.
Get the full story on our sister site Medical Design & Outsourcing.